Barnaby Pickering
Senior Writer
Barnaby lives and works in Yorkshire. Having graduated from University College London with a master's degree in biomedical engineering in 2020, Barnaby is passionate about cutting-edge medical technology. Key areas of focus for Barnaby include diabetes, nanotechnology, machine learning and artificial intelligence.
Latest From Barnaby Pickering
Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future
PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.
Investor Eye: A Licensing-Based Approach May Be Best For Revolutionary IP
Keeping a firm grip on one’s IP is a cornerstone of most innovative businesses. However, Robert Cote, CEO of Cote Capital, believes that if the idea is good enough to keep close, it’s good enough to license out.
The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted
Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.
Execs On The Move: April 2023
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Swedish Drug And Device To Go Head-To-Head In The GERD Space
Two Swedish companies are working on tackling GERD – one with a drug, one with a device.
Belgium's Sequana Sits At Junction Between Pharma And Medtech
The company’s dual drug-device development pipeline is progressing well, especially its direct sodium removal therapy for congestive heart failure.